Auchincloss and Griffith Introduce Bill to Modernize Clinical Trials

Representatives Jake Auchincloss (D-MA) and Morgan Griffith (R-VA) introduced the proposed Faster Clinical Trials Act on October 22, 2026. The sponsors describe the bill as an effort to speed development of new treatments, invest in clinical research, and sustain U.S. leadership in biomedical innovation. Their announcement frames the legislation around a gap between scientific progress and the ability of the U.S. clinical research enterprise to test and move potential treatments into care settings. It argues that fragmented processes and friction in integrating trials into U.S. sites of care have slowed development, testing, and approval.

The proposal would upgrade what the sponsors call the country’s science infrastructure: clinical research data, research sites, and clear standards for treatment development. At the center of the plan is a Center for Clinical Trial Innovation (CCI) within the U.S. Food and Drug Administration’s drug review center. The stated goal is to improve clinical-trial operations while preserving the FDA’s high standards for safety and effectiveness. The source announcement also describes trial networks that prioritize community and rural care sites, bringing research closer to everyday care rather than relying solely on established research institutions.

For GovCon firms, the potential relevance is in implementation rather than an immediate bid opportunity. If the bill advances and is enacted, the proposed center and networks could prompt later agency requirements for clinical research services, site operations, health information technology, data integration, training, and regulatory support. Providers with experience connecting community and rural care locations to research programs may find the policy direction relevant to capability planning, but the announcement does not specify program budgets, acquisition strategies, contract vehicles, or who would deliver the work.

Procurement teams should treat this as proposed legislation, not a funded opportunity. The source identifies no solicitation, contract value, grant funding, submission deadline, or procurement schedule. Any contracting activity would depend on the bill advancing, its final enacted provisions, and subsequent FDA or other agency implementation and funding decisions. Contractors can monitor legislative developments and assess whether their capabilities align with the proposal’s emphasis on trial access, modernized research infrastructure, and maintaining rigorous safety and effectiveness standards, while avoiding assumptions that a near-term procurement is imminent.

• Introduced: The Faster Clinical Trials Act was released on October 22, 2026, by Representatives Jake Auchincloss and Morgan Griffith.
• Proposed FDA structure: The bill would establish a Center for Clinical Trial Innovation within the FDA’s drug review center.
• Research-site emphasis: Proposed trial networks would prioritize community and rural care sites and integrate trials into everyday care.
• Infrastructure focus: The proposal targets clinical research data, research sites, and clear standards to support treatment development.
• Stated policy objective: The sponsors seek faster treatment development and U.S. biomedical innovation while preserving FDA safety and effectiveness standards.
• Potential contractor capabilities: Clinical research operations, health IT, data integration, training, and regulatory support may be relevant if implementation generates requirements.
• No active procurement identified: The announcement contains no contract value, solicitation, grant amount, acquisition vehicle, or submission deadline.
• Action for industry: Track the bill and later agency implementation; evaluate community- and rural-site capabilities without treating the proposal as funded work.